Before dementia genetic testing, ask what results the test can produce—risk-related, disease-causing, negative, or uncertain—and what each would mean. Also ask whether the result could change care, affect relatives, or create emotional and insurance consequences. Genetic counseling is a discussion that helps you understand those possibilities before deciding whether to test. Because the supplied evidence focuses on Alzheimer's disease, ask whether it applies to the specific dementia condition being evaluated.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- Risk result or disease-causing result?
- What would an APOE result mean?
- Could testing find a strongly predictive variant?
- What do negative and uncertain results tell you?
- What should you settle before saying yes?
Risk result or disease-causing result?
Start by asking, "Would this test estimate risk, or look for a variant that strongly predicts disease?" The distinction matters because most Alzheimer's cases involve multiple genes alongside lifestyle and environmental factors, rather than a single inherited cause, according to the National Institute on Aging. A risk variant changes probability but does not diagnose Alzheimer's or guarantee that it will develop.
A disease-causing, or pathogenic, variant is a genetic change with evidence that it can cause a particular disorder. Ask the counselor to explain the possible result categories in plain language:.
- What would a positive result establish—and what would it not establish?
- Could the laboratory report an uncertain finding?
- What important genetic causes would this test not assess?
- Would the meaning differ for someone with symptoms and someone without them?
What would an APOE result mean?
APOE is a gene associated with Alzheimer's risk. An APOE ε4 result does not mean that someone has Alzheimer's or will inevitably develop it. Some ε4 carriers never develop the disease, and the strength of the association varies by genetic ancestry.
Two ε4 copies are associated with higher risk than one. APOE ε2 may be protective, while ε3 is generally considered neutral. These remain risk associations, not diagnostic findings. Before testing, ask:.
- Will the test include APOE?
- Am I prepared to receive a probability rather than a prediction?
- How will ancestry affect the interpretation?
- Would knowing the result change any decision I can make now?
Could testing find a strongly predictive variant?
Pathogenic variants in APP, PSEN1, or PSEN2 can strongly predict younger-onset autosomal-dominant Alzheimer's. If a parent carries such a variant, each child has a 50% chance of inheriting it and a very strong probability of disease if it is inherited. These variants are rare.
They account for only 10% to 15% of younger-onset cases, and younger-onset disease represents under 10% of Alzheimer's cases. Testing is therefore most relevant when early symptoms occur alongside a strong family history. Ask whether an affected relative should be tested first. Also ask what a positive finding would mean for siblings, children, and other blood relatives—and whether you want to learn information that could indirectly reveal their risk.
What do negative and uncertain results tell you?
A negative result may be reassuring, but it does not always rule out inherited risk or disease. The test may not include the relevant cause, or it may fail to detect a causal alteration. A variant of uncertain significance, often shortened to VUS, means available evidence is insufficient or conflicting.
It cannot confirm or exclude a dementia diagnosis or future risk. Testing affected and unaffected relatives can sometimes help clarify the finding, according to MedlinePlus Genetics. Ask exactly what "negative" would mean for the proposed test. For an uncertain result, ask whether the laboratory may reinterpret it later, how you would receive an update, and whether family testing could add useful evidence.
What should you settle before saying yes?
Routine Alzheimer's genetic testing is not generally recommended. APOE testing is used mainly in research or selected clinical situations involving treatment planning, while pre- and post-test counseling helps people decide whether to receive and use results, according to the Alzheimer's Association. Decide in advance whom you would tell and what support you might need after an unexpected result.
Results can affect blood relatives as well as the person tested, even when relatives did not request testing. In the United States, the Genetic Information Nondiscrimination Act restricts the use of genetic information in health-insurance and employment decisions. It does not cover life, disability, or long-term-care insurance, as the National Human Genome Research Institute explains. Before testing, ask how results will be documented and consider any insurance decisions that could be affected.
